Maxim Shmarov, head of the molecular biotechnology laboratory at the Gamaleya Center, talked about when the second phase of clinical trials of the new flu vaccine in the form of a nasal spray will be completed, reports TASS. According to Maxim Shmarov, the new drug Gam-Flu-Vac-Quadri is intended for immunizing the population against four strains of flu and coronavirus infection. This vaccine is made in liquid form and is sprayed into a person’s nasal cavity using a special attachment on a syringe. Currently, the developers at the Center are conducting the second phase of clinical trials (CT) of the drug. According to legislative norms, registration of the new vaccine will only be possible after the successful completion of the third phase of trials. Based on the results, specialists will conclude how effectively the new drug protects people from these infections. The nasal vaccine variant being studied now will be used for adult immunization. For it to be used for children’s immunoprophylaxis, special studies involving children will be conducted after obtaining the registration certificate for the vaccine. During the coronavirus pandemic, Russian scientists proposed different nasal vaccine options in 2022. One of them is the vector intranasal vaccine Corfluvec, developed at the Smorodintsev Institute. It is intended for simultaneous immunoprophylaxis of flu and coronavirus. At the same time, a nasal spray vaccine was created at the Gamaleya Center; however, for their vector vaccine named Sputnik V, specialists used adenovirus instead of the flu virus as in Corfluvec. In 2022, the company “Generium” registered its own preparation for vaccination in the form of a nasal spray, Salnavac.